Fumero Andrea, Lapenna Elisabetta, Taramasso Maurizio, Alfieri Ottavio
Dipartimento di Chirurgia Cardio-Toraco-Vascolare, Ospedale Universitario San Raffaele, Milano.
G Ital Cardiol (Rome). 2011 Sep;12(9):599-605. doi: 10.1714/926.10174.
The aim of this study was to evaluate the quality of life (QoL) benefit of patients with chronic refractory angina treated with spinal cord stimulation (SCS) in our experience.
Between February 1998 and August 2010, 100 patients with chronic refractory angina who could not benefit from myocardial revascularization underwent SCS at the San Raffaele Scientific Institute of Milan (Italy). All patients were prospectively followed up at our outpatient clinic. The Spitzer index was used to evaluate QoL of patients before the procedure and at follow-up.
Mean age was 66 ± 8 years (range 46-79). Ninety-four patients (94%) were in CCS class III-IV (mean CCS class 3.5 ± 0.1) and 62 patients (62%) were in NYHA class III-IV (mean NYHA class 2.6 ± 0.1). The preoperative Spitzer index was 4.4 ± 1.4. Mean angina episodes per week were 12.6 ± 9.3 and mean consumption of sublingual nitrates was 11.0 ± 9.4. At follow-up, overall mortality was 11% (n = 11), and cardiovascular death was 3%. A reduction in angina episodes per week >50% was observed in 88% of patients (from 12.6 ± 9.3 to 2.7 ± 1.13; p<0.0001). Mean consumption of sublingual nitrates decreased from 11.0 ± 9.4 to 2.3 ± 0.1 (p<0.0001). The Spitzer index significantly improved (from 4.4 ± 0.1 to 2.3 ± 0.1; p<0.0001). NYHA class and CCS class decreased from 2.6 ± 0.1 to 2.0 ± 0.1 and from 3.5 ± 0.1 to 1.7 ± 0.1, respectively (both p<0.0001).
SCS is an effective and safe therapeutic option for patients with chronic refractory angina and it is associated with improved functional status and QoL at follow-up.
本研究旨在根据我们的经验评估接受脊髓刺激(SCS)治疗的慢性难治性心绞痛患者的生活质量(QoL)获益情况。
1998年2月至2010年8月期间,100例无法从心肌血运重建中获益的慢性难治性心绞痛患者在意大利米兰圣拉斐尔科学研究所接受了SCS治疗。所有患者均在我们的门诊进行前瞻性随访。采用斯皮策指数评估患者术前及随访时的生活质量。
平均年龄为66±8岁(范围46 - 79岁)。94例患者(94%)为加拿大心血管学会(CCS)分级III - IV级(平均CCS分级3.5±0.1),62例患者(62%)为纽约心脏协会(NYHA)分级III - IV级(平均NYHA分级2.6±0.1)。术前斯皮策指数为4.4±1.4。每周平均心绞痛发作次数为12.6±9.3次,舌下硝酸酯类药物平均消耗量为11.0±9.4。随访时,总死亡率为11%(n = 11),心血管死亡率为3%。88%的患者每周心绞痛发作次数减少>50%(从12.6±9.3次降至2.7±1.13次;p<0.0001)。舌下硝酸酯类药物平均消耗量从11.0±9.4降至2.3±0.1(p<0.0001)。斯皮策指数显著改善(从4.4±0.1升至2.3±0.1;p<0.0001)。NYHA分级和CCS分级分别从2.6±0.1降至2.0±0.1和从3.5±0.1降至1.7±0.1(均p<0.0001)。
SCS是慢性难治性心绞痛患者的一种有效且安全的治疗选择,并且与随访时功能状态和生活质量的改善相关。